Wu Zunyou: Infected people who have been vaccinated have a low risk of new crown sequelae
On October 13, at the press conference of the State Council's joint prevention and control mechanism , China Center for Disease Control and Prevention chief expert in epidemiology Wu Zunyou said that the new crown virus Sequelae are common in severe cases, but can also occur in mild cases. People who have been vaccinated have a lower risk of sequelae after infection with new crown than those who have not been vaccinated. Wu Zunyou said that the best way to prevent the sequelae of the new crown virus is to prevent the new crown virus infection.
New progress has been made in the research and development of my country's new coronavirus vaccine
According to Xinhua News AgencyBeijing on October 12, the reporter recently learned from the scientific research team of the Joint Prevention and Control Mechanism of the State Council and related scientific research teams that my country adheres to multiple technical routes in parallel, and the new coronavirus New progress has been made in the research and development of virus vaccines. Recently, another adenovirus vector vaccine for inhalation and a recombinant protein vaccine have been approved in China, which can be used for emergency use in a specified population six months after the completion of two doses of inactivated vaccine . .
HPV vaccine free vaccination for school-age girls in Yantai, Shandong started
On October 8, the launching ceremony of the free HPV vaccine project for school-age girls in Yantai City and the project implementation training meeting were held. Starting from 2022, Yantai City will implement the free HPV vaccination project for girls of appropriate age.
R&D News
Wantai Bio: Phase III Clinical Trial of Nasal Spray Vaccine Obtained Key Data
Wantai Bio announced on October 10 that recently, the nasal spray new crown vaccine developed by the company in cooperation with Xiamen University and Hong Kong University has been Completed the interim master data analysis of the Phase III clinical trial and obtained key data. The intellectual property rights and future benefits generated by the nasal spray new crown vaccine during the research and development process are enjoyed according to the specific circumstances and contributions of the parties and the agreement signed by the three parties.
Oxford/AstraZeneca nasal spray Covid-19 vaccine fails in early trials Failed in early trials. The University of Oxford said on Tuesday (October 11) local time that the nasal spray vaccine only elicited mucosal antibody responses in "a small number of subjects" and that the systemic immune response was weaker than the intramuscular vaccine.
Vaccine industry
published an article on July 22, Olin Bio R & D staff. On October 14, the official WeChat account of Olin Bio released news, Shanghai Stock Exchange and China Securities Index Co., Ltd. officially announced In the release arrangement of the growth index of the Shanghai Stock Exchange Science and Technology Innovation Board, Olin Bio, as the only two selected enterprises in the Sichuan area, was successfully selected into the list of sample enterprises to be released. It marks that the innovation and growth potential of Olin Bio has been fully recognized by the capital market.
Wantai Bio's pre-increase in net profit for the first three quarters exceeded 216%
Wantai Bio disclosed its performance forecast for the first three quarters of 2022 on the evening of October 11, with an estimated net profit of 3.75 billion to 3.95 billion yuan, a year-on-year increase of 216%- 232%. Wantai Bio said that the company's bivalent cervical cancer vaccine continued to maintain a boom in production and sales, with rapid growth in revenue and profit; due to the impact of the new crown pneumonia epidemic at home and abroad, the company's new crown raw materials and new crown detection reagents The revenue and profit have achieved rapid growth.
On September 27, the quadrivalent meningococcal polysaccharide conjugate vaccine was launched in Shanghai. CanSino Bio WeChat publicNo. fig
CanSino Bio MCV4 and other meningitis vaccines have been inoculated
On October 10th, CanSino Bio released the results of the performance meeting. CanSino said that its two-valent meningococcal polysaccharide conjugate vaccine MCV2 Menaixi and quadrivalent meningococcal polysaccharide conjugate vaccine MCV4 Manhaixin have now completed the access to more than 20 provinces, and have been inoculated in various provinces one after another. .
Clover Bio is expected to complete the new crown vaccine registration application in the fourth quarter
On October 9th, Clover Bio announced that Clover Bio's primary new crown candidate vaccine SCB-2019 (CpG 1018/aluminum adjuvant) has submitted to the China National Medical Products Administration, Significant progress has been made in the submission of registration applications for European Medicines Agency and World Health Organization , which is expected to be completed in the fourth quarter of 2022. (People's Daily)
